The whole bioscience industry still relies on 'pen to paper' or 'finger to keyboard'documentation for Research and Development processes. Although this is unavoidable due to the large amount of human dependent tasks in these processes, it does significantly impact downstream processes like Quality Assurance and investment decision making.

Panorama Laboratories is building a suite of sensors that digitally documents the actions that require human interaction. This suite of sensors will enable the fastest possible reaction times to errors and allow for our AI to compile quality related documentation for these human dependent actions.

Omnigen is aiming to use biological knowledge and research in a positive and useful way for society. We do this by, for example, bring the results of scientific research closer to the broad public. We also develop methods to make the treatment of illnesses better and more efficient and we do research to accelerate and professionalize the development of partners.

After a year of development, on March 11th the Janssen COVID-19 vaccine was approved in the European Union. The rapid development of the vaccine shows the power of collaborations. In Februari 2020, just after the outbreak of Sars-Voc-2, Janssen started a collaboration with the Leiden University to investigate the, at that point in time, 10 candidates. After successful identification of the vaccine-candidate, Janssen, LUMC and the Center for Human Drug Research teamed up in September 2020 to design and execute the phase 2a trial to determine the optimal vaccination dose and schedule.

At the LSH010-SmB Cafe, Ingrid de Visser-Kamerling, Associate director at the Centre for Human Drug Research, will give an insight into the research and development of the Janssen Vaccine. Additionally she will highlight the challenges that were overcome during the development that made it possible to rapidly develop a vaccine.